Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 6Active not recruiting 6Completed 4Not yet recruiting 2Unknown 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Tumor-Agnostic 2Head & Neck 2Dermatologic 2Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Melanoma 5Neoplasms 4Recurrence 3Neoplasm Metastasis 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Basal Cell 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2Sarcoma 2Pancreatic Neoplasms 2Head and Neck Neoplasms 2Cutaneous Squamous Cell Carcinoma 2Colorectal Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Recurrent Squamous Cell Carcinoma of Head 1Ovarian Neoplasms 1Natural Killer/T-cell Lymphoma 1Multiple Myeloma 1Malignant Solid Tumor 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Kidney Neoplasms 1Hemangiosarcoma 1Glioma 1Glioblastoma 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Squamous Cell 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Neoplasms × cemiplimab × Clear all
NCT05259696 2025-08-20

GLIMMER-01

Palleon Pharmaceuticals, Inc.

Phase 1/2 Completed
69 enrolled 13 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT03005782 2024-05-01

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

Regeneron Pharmaceuticals

Phase 1 Completed
333 enrolled
Tumor-Agnostic

Neoplasms

NCT05302297 2022-12-13

TOSCA

Sanofi

Completed
305 enrolled
Tumor-Agnostic

Neoplasms

NCT02423863 2020-12-17

Poly-ICLC

Oncovir, Inc.

Phase 2 Completed
26 enrolled
DermatologicHead & NeckSarcoma

Head and Neck Neoplasms, Melanoma, Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡